SG10201500140VA - Human antibodies against human tissue factor - Google Patents

Human antibodies against human tissue factor

Info

Publication number
SG10201500140VA
SG10201500140VA SG10201500140VA SG10201500140VA SG10201500140VA SG 10201500140V A SG10201500140V A SG 10201500140VA SG 10201500140V A SG10201500140V A SG 10201500140VA SG 10201500140V A SG10201500140V A SG 10201500140VA SG 10201500140V A SG10201500140V A SG 10201500140VA
Authority
SG
Singapore
Prior art keywords
antibodies against
tissue factor
human
human antibodies
human tissue
Prior art date
Application number
SG10201500140VA
Inventor
Sandra Verploegen
David P E Satijn
Rene M A Hoet
Paul Parren
De Winkel Jan Van
Vibeke Miller Breinholt
Eva Ehrnrooth
Ole Baadsgaard
Tom Vink
Willem Karel Bleeker
Mischa Houtkamp
Maroeska Oudshoorn
Jong Rob N De
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of SG10201500140VA publication Critical patent/SG10201500140VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201500140VA 2008-12-09 2009-12-09 Human antibodies against human tissue factor SG10201500140VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20133508P 2008-12-09 2008-12-09
DKPA200801744 2008-12-09

Publications (1)

Publication Number Publication Date
SG10201500140VA true SG10201500140VA (en) 2015-03-30

Family

ID=59050110

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201500140VA SG10201500140VA (en) 2008-12-09 2009-12-09 Human antibodies against human tissue factor

Country Status (21)

Country Link
US (6) US9150658B2 (en)
EP (3) EP2376537B1 (en)
JP (6) JP5860285B2 (en)
KR (2) KR101736447B1 (en)
CN (2) CN102317319B (en)
AU (1) AU2009324412B2 (en)
BR (1) BRPI0922350B8 (en)
CA (2) CA3017575A1 (en)
DK (1) DK2376537T3 (en)
EA (1) EA201100923A1 (en)
ES (1) ES2604635T3 (en)
IL (1) IL212856A (en)
MX (2) MX338754B (en)
NZ (1) NZ786274A (en)
PL (1) PL2376537T3 (en)
PT (1) PT2376537T (en)
SG (1) SG10201500140VA (en)
SI (1) SI2376537T1 (en)
UA (1) UA109633C2 (en)
WO (1) WO2010066803A2 (en)
ZA (1) ZA201103723B (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578397B1 (en) * 2002-11-15 2012-12-26 Genmab A/S Human monoclonal antibodies against cd25
CA2745439C (en) * 2008-12-03 2019-10-15 Genmab A/S Antibody variants having modifications in the constant region
UA109633C2 (en) * 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
CN107253992B (en) 2010-05-27 2022-03-11 根马布股份公司 Monoclonal antibody against HER2
EP2582728B1 (en) * 2010-06-15 2017-08-23 Genmab A/S Human antibody drug conjugates against tissue factor
TW202323302A (en) * 2010-11-30 2023-06-16 日商中外製藥股份有限公司 Cytotoxicity-inducing therapeutic agent
US8722044B2 (en) * 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
WO2012143523A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
JP2014514314A (en) * 2011-04-20 2014-06-19 ゲンマブ エー／エス Bispecific antibodies against HER2 and CD3
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. Antibody variants and uses thereof
US9555109B2 (en) * 2012-01-20 2017-01-31 University Of Cincinnati Method of inhibiting cell proliferation induced by alternatively spliced tissue factor by administering a monoclonal antibody
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
KR20200024345A (en) 2013-01-10 2020-03-06 젠맵 비. 브이 Human igg1 fc region variants and uses thereof
US20160237163A1 (en) * 2013-10-02 2016-08-18 Suri Technologies Ltd. Patient-specific immunotherapy for treating heterogeneous tumors
WO2015075201A1 (en) 2013-11-21 2015-05-28 Genmab A/S Antibody-drug conjugate lyophilised formulation
WO2016077720A1 (en) * 2014-11-14 2016-05-19 Protein One, Llc Binding agents and uses thereof
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL303543A (en) 2015-02-18 2023-08-01 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP6803339B2 (en) 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド Therapeutic pooled blood apoptotic cell preparations and their use
CN106467574B (en) * 2015-08-20 2019-09-20 复旦大学 Target antibody, the preparation method and use of tissue factor
SI3347054T1 (en) 2015-09-11 2021-08-31 Genmab A/S Dosing regimens for anti-tf-antibody drug-conjugates
KR20180110141A (en) 2016-02-18 2018-10-08 엔리벡스 테라퓨틱스 리미티드 Combination of immunotherapy and cytokine regulating therapy to treat cancer
US10676537B2 (en) 2016-08-22 2020-06-09 Fudan University Antibody targeted to tissue factor, preparation method therefor, and use thereof
CN106938051B (en) 2016-08-22 2019-10-11 复旦大学 Target the antibody-drug conjugates of tissue factor
EP3534953A4 (en) * 2016-11-02 2020-10-07 Vanderbilt University Human zika virus antibodies and methods of use therefor
TW201922796A (en) * 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same
MX2020004265A (en) * 2017-11-02 2020-08-03 Genmab As Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer.
KR20200118029A (en) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
TWI841554B (en) * 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
EA202092136A1 (en) 2018-05-07 2021-03-22 Генмаб А/С METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG
EP3814379A4 (en) 2018-05-07 2022-03-30 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
AU2019321442A1 (en) * 2018-08-16 2021-02-11 Genmab A/S Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
TWI844571B (en) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
CN109840471B (en) * 2018-12-14 2023-04-14 天津大学 Feasible road segmentation method based on improved Unet network model
CA3123046A1 (en) * 2018-12-21 2020-06-25 Board Of Regents, The University Of Texas System Phosphorylated dicer antibody and methods of use thereof
CN113645996B (en) * 2019-02-01 2024-04-02 新石生物制药有限公司 Anti-claudin 18 antibodies and methods of use thereof
KR20240046282A (en) 2019-04-17 2024-04-08 노보 노르디스크 에이/에스 Bispecific antibodies
TW202131954A (en) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
EP4055051A1 (en) 2019-11-07 2022-09-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
US20230173093A1 (en) 2020-04-10 2023-06-08 Seagen Inc. Charge variant linkers
MX2022015375A (en) 2020-06-29 2023-01-16 Genmab As Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer.
CA3184987A1 (en) * 2020-07-10 2022-01-13 Thi-Sau Migone Inflammatory disease treatment using anti-tissue factor antibodies
WO2022056197A1 (en) * 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
UY39415A (en) 2020-09-11 2022-03-31 Janssen Biotech Inc METHODS AND COMPOSITIONS FOR MODULATING IMMUNITY MEDIATED BY BETA CHAINS
IL302402A (en) 2020-11-08 2023-06-01 Seagen Inc Combination therapy
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
JP2024514673A (en) 2021-04-20 2024-04-02 シージェン インコーポレイテッド Regulation of antibody-dependent cellular cytotoxicity
CA3221398A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
TW202342517A (en) * 2022-01-12 2023-11-01 美商艾康尼醫療有限責任公司 Inflammatory disease treatment using anti-tissue factor antibodies
WO2023178289A2 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US835A (en) 1838-07-12 X i i i x
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (en) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5437864A (en) 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
ATE113846T1 (en) 1988-06-21 1994-11-15 Genentech Inc THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF MYOCARDIAL INFARCTS.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE172879T1 (en) 1989-08-09 1998-11-15 Rhomed Inc DIRECT RADIO LABELING OF ANTIBODIES AND OTHER PROTEINS USING TECHNETIUM OR RHENIUM
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
DE69034135T3 (en) 1989-12-22 2012-08-23 Laboratoires Serono S.A. DNA constructs to activate and alter the expression of endogenous genes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
JP3149960B2 (en) 1991-01-24 2001-03-26 財団法人化学及血清療法研究所 Method for quantifying human tissue factor
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JPH05244988A (en) 1992-03-04 1993-09-24 Green Cross Corp:The Anti-tissue factor monoclonal antibody and immunosuppressant with the same
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994005328A1 (en) 1992-08-28 1994-03-17 The Scripps Research Institute Inhibition of tumor metastasis via neutralization of tissue factor function
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5879677A (en) 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
JP3801196B2 (en) 1993-03-09 2006-07-26 ジェンザイム・コーポレイション Isolation of the target compound from milk
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5879687A (en) 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
CA2194369C (en) 1994-07-11 2004-08-31 Philip E. Thorpe Methods and compositions for the specific coagulation of vasculature
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
ATE266726T1 (en) 1995-06-07 2004-05-15 Ortho Pharma Corp CDR-TRANSPLANTED ANTIBODIES AGAINST ßTISSUE FACTORß AND METHOD FOR USE THEREOF
KR970029803A (en) 1995-11-03 1997-06-26 김광호 Precharge Circuit of Semiconductor Memory Device
JPH09302000A (en) 1996-05-16 1997-11-25 Chemo Sero Therapeut Res Inst Anti-tissue factor monoclonal antibody and determination of tissue factor coagulation activity using the monoclonal antibody
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20040229282A1 (en) 1997-03-10 2004-11-18 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US6719977B1 (en) 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
ATE512225T1 (en) 1998-04-03 2011-06-15 Chugai Pharmaceutical Co Ltd HUMANIZED ANTIBODY AGAINST HUMAN TISSUE FACTOR (TF) AND METHOD FOR CONSTRUCTING SUCH HUMANIZED ANTIBODY.
EP1728865A1 (en) 1998-09-04 2006-12-06 Aventis Pasteur Limited Treatment of cervical cancer
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
ATE276199T1 (en) 1999-02-03 2004-10-15 Biosante Pharmaceuticals Inc METHODS FOR PRODUCING THERAPEUTIC CALCIUM PHOSPHATE PARTICLES
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE60037896D1 (en) 1999-07-29 2008-03-13 Medarex Inc HUMAN ANTIBODIES AGAINST HER2 / NEU
US6984720B1 (en) 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
JP2001213804A (en) 2000-01-31 2001-08-07 Chugai Pharmaceut Co Ltd Antitissue factor antibody complex
EP1263960A2 (en) 2000-03-16 2002-12-11 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
AU2002235141A1 (en) 2000-11-27 2002-06-03 Geron Corporation Glycosyltransferase vectors for treating cancer
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
US20040180051A1 (en) 2001-03-26 2004-09-16 Koji Suzuki Blood rheology improving agents
HU229776B1 (en) 2001-08-23 2014-07-28 Genmab As Human antibodies specific for interleukin 15 (il-15)
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
DE60232733D1 (en) 2001-08-30 2009-08-06 Sinai School Medicine ALTERNATIVELY PLIED CIRCULATING TISSUE FACTOR
CN1575302A (en) * 2001-10-02 2005-02-02 诺沃挪第克公司 Human tissue factor antibodies
US20050169927A1 (en) * 2001-10-02 2005-08-04 Novo Nordisk A/S Human tissue factor antibodies
TWI338009B (en) 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003037361A2 (en) 2001-11-02 2003-05-08 Novo Nordisk Health Care Ag Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
AP2004003113A0 (en) 2002-02-22 2004-09-30 Prophy Med Ab Use of an inhibitor or antagonist against tissue factor
CA2483909A1 (en) 2002-05-01 2003-11-13 Schering Aktiengesellschaft Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
WO2004007557A2 (en) 2002-07-12 2004-01-22 Novo Nordisk A/S Tf antagonist
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2004039842A2 (en) * 2002-10-31 2004-05-13 Novo Nordisk A/S Humanized tissue factor antibodies
AU2003275947A1 (en) 2002-11-06 2004-06-07 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
AU2003275948A1 (en) 2002-11-06 2004-06-07 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
EP1578397B1 (en) 2002-11-15 2012-12-26 Genmab A/S Human monoclonal antibodies against cd25
ES2373947T3 (en) 2002-12-16 2012-02-10 Genmab A/S HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUCINE 8 (IL-8).
WO2004064870A2 (en) 2003-01-22 2004-08-05 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
US20060034846A1 (en) 2003-04-14 2006-02-16 Mirella Ezban Use of TF antagonists
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
BRPI0410875A (en) 2003-05-30 2006-07-04 Centocor Inc Tumor Factor Growth Inhibition Method
WO2005000896A2 (en) 2003-05-30 2005-01-06 Genentech, Inc. Polypeptides that bind an anti-tissue factor antibody and uses thereof
US7605235B2 (en) * 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
ES2527102T3 (en) 2003-06-19 2015-01-20 Genentech, Inc. Compositions and methods for the treatment of disorders related to coagulation
WO2005025623A2 (en) 2003-07-28 2005-03-24 Emory University Ef-24-factor vii conjugates
WO2005020927A2 (en) 2003-08-29 2005-03-10 Centocor, Inc. Method of promoting graft survival with anti-tissue factor antibodies
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
EP2865687A1 (en) 2003-12-10 2015-04-29 E. R. Squibb & Sons, L.L.C. IP-10 antibodies and their uses
EP1744734A2 (en) 2004-02-20 2007-01-24 Novo Nordisk A/S Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
JP4958555B2 (en) 2004-09-22 2012-06-20 協和発酵キリン株式会社 Stabilized human IgG4 antibody
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
WO2007097810A2 (en) 2005-10-21 2007-08-30 Genentech, Inc. Treatment for antiphospholipid-syndrome-related pregnancy complications
EA014900B1 (en) 2005-11-07 2011-02-28 Зе Скрипс Ресеч Инститьют Compositions and methods for controlling tissue factor signaling specificity
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007076091A2 (en) 2005-12-22 2007-07-05 Genentech, Inc. Treatment of viral infections using a tissue factor inhibitor
US20080311034A1 (en) 2007-04-30 2008-12-18 Anderson Glenn M Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector Function
UA109633C2 (en) * 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
EP2582728B1 (en) 2010-06-15 2017-08-23 Genmab A/S Human antibody drug conjugates against tissue factor

Also Published As

Publication number Publication date
CA3017575A1 (en) 2010-06-17
KR20110104944A (en) 2011-09-23
EP3159358B1 (en) 2023-10-11
WO2010066803A2 (en) 2010-06-17
EP2376537B1 (en) 2016-09-28
KR101998492B1 (en) 2019-07-09
CA2746101A1 (en) 2010-06-17
EP4279140A3 (en) 2024-01-31
US9150658B2 (en) 2015-10-06
ZA201103723B (en) 2012-09-26
JP2022078018A (en) 2022-05-24
JP7069095B2 (en) 2022-05-17
BRPI0922350B8 (en) 2021-05-25
MX338754B (en) 2016-04-29
CN106632678B (en) 2022-05-31
MX2011005669A (en) 2011-06-17
IL212856A (en) 2016-09-29
JP6592491B2 (en) 2019-10-16
EA201100923A1 (en) 2011-12-30
JP5860285B2 (en) 2016-02-16
PT2376537T (en) 2016-12-26
EP2376537A2 (en) 2011-10-19
JP2018038418A (en) 2018-03-15
UA109633C2 (en) 2015-09-25
EP4279140A2 (en) 2023-11-22
SI2376537T1 (en) 2017-02-28
JP2012511314A (en) 2012-05-24
CN102317319B (en) 2016-06-29
MX355181B (en) 2018-04-09
AU2009324412A1 (en) 2011-06-30
KR101736447B1 (en) 2017-05-16
PL2376537T3 (en) 2017-06-30
KR20170056025A (en) 2017-05-22
BRPI0922350B1 (en) 2021-01-12
ES2604635T3 (en) 2017-03-08
US9714297B2 (en) 2017-07-25
DK2376537T3 (en) 2017-01-23
US20210171657A1 (en) 2021-06-10
US20180044431A1 (en) 2018-02-15
CA2746101C (en) 2018-10-30
JP2024001285A (en) 2024-01-09
JP2020022461A (en) 2020-02-13
JP6236056B2 (en) 2017-11-22
CN102317319A (en) 2012-01-11
US20160053020A1 (en) 2016-02-25
CN106632678A (en) 2017-05-10
EP3159358A1 (en) 2017-04-26
JP2016138089A (en) 2016-08-04
WO2010066803A3 (en) 2010-08-19
AU2009324412B2 (en) 2016-04-21
NZ786274A (en) 2023-09-29
BRPI0922350A2 (en) 2016-01-12
US20190169311A1 (en) 2019-06-06
IL212856A0 (en) 2011-07-31
US20230416403A1 (en) 2023-12-28
US20110300156A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
ZA201103723B (en) Human antibodies against human tissue factor
HK1195775A1 (en) Antibodies against human angiopoietin
SI2949666T1 (en) Human anti-alpha-synuclein antibodies
EP2207803A4 (en) Cd9-specific human antibodies
EP2179030A4 (en) Human disc tissue
GB0807018D0 (en) Antibodies and treatment
ZA201008748B (en) Humanized antibodies against human interferon-alpha
IL212795A0 (en) Fully human antibodies against n-cadherin
GB0815788D0 (en) Therapeutic antibodies
EP2344533A4 (en) Tmprss4-specific human antibody
EP2324059A4 (en) Anti-pamp therapeutic antibodies
IL216440A0 (en) Antibodies against human ccn1 and uses thereof
GB0812940D0 (en) Medical implant
HRP20190159T1 (en) Human anti-alpha-synuclein antibodies
SG10202006468XA (en) Human antibodies against human tissue factor
GB0805534D0 (en) Medical Aid
GB0800146D0 (en) Medical aid
GB0809735D0 (en) Medical implant
GB0809820D0 (en) Modified tissues
IL212647A0 (en) Tissue adhesive
GB0819010D0 (en) Medical uses
GB0809339D0 (en) Medical uses
GB0809333D0 (en) Medical uses